Therapeutic potential of "rexinoids" in cancer prevention and treatment

Takemi Tanaka, Luigi M. De Luca

Research output: Contribution to journalArticle

Abstract

Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.

Original languageEnglish (US)
Pages (from-to)4945-4947
Number of pages3
JournalCancer Research
Volume69
Issue number12
DOIs
StatePublished - Jun 15 2009

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this